TY - JOUR
T1 - Vibration-Controlled Transient Elastography–Based Parameters Predict Clinical Outcomes in Liver Transplant Recipients
AU - Baral, Alok
AU - Garg, Shreya
AU - Nguyen, Madison
AU - Razzaq, Rehan
AU - Ang, Audrey
AU - Khan, Hiba
AU - Vainer, Dylan
AU - Patel, Vaishali
AU - Roache, Geneva
AU - Muthiah, Mark
AU - Yakubu, Idris
AU - Kumaran, Vinay
AU - Bui, Anh T.
AU - Siddiqui, Mohammad Shadab
N1 - Publisher Copyright:
© 2024 AGA Institute
PY - 2024/12
Y1 - 2024/12
N2 - Background and Aims: Vibration-controlled transient elastography (VCTE) is used in clinical practice to risk-stratify liver transplant (LT) recipients; however, there are currently little data demonstrating the relationship between VCTE and clinical outcomes. Methods: A total of 362 adult LT recipients with successful VCTE examination between 2015 and 2022 were included. Presence of advanced fibrosis was defined as liver stiffness measurement (LSM) ≥10.5 kPa and hepatic steatosis as controlled attenuation parameter (CAP) ≥270 dB/m. The outcomes of interest included all-cause mortality, myocardial infarction (MI), and graft cirrhosis using cumulative incidence analysis that accounted for the competing risks of these outcomes. Results: The LSM was elevated in 64 (18%) and CAP in 163 (45%) LT recipients. The baseline LSM values were similar in patients with elevated vs normal CAP values. After a median follow-up of 65 (interquartile range, 20–140) months from LT to baseline VCTE, 66 (18%) patients died, 12 (3%) developed graft cirrhosis, and 18 (5%) experienced an MI. Baseline high LSM was independently associated with all-cause mortality (hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.11–3.50; P = .02) and new onset cirrhosis (HR, 6.74; 95% CI, 2.08–21.79; P < .01). A higher CAP value was significantly and independently associated with increased risk of experiencing a MI over study follow-up (HR, 4.14; 95% CI, 1.29–13.27; P = .017). Conclusions: The VCTE-based parameters are associated with clinical outcomes and offer the potential to be incorporated into clinical risk-stratification strategies to improve outcomes among LT recipients.
AB - Background and Aims: Vibration-controlled transient elastography (VCTE) is used in clinical practice to risk-stratify liver transplant (LT) recipients; however, there are currently little data demonstrating the relationship between VCTE and clinical outcomes. Methods: A total of 362 adult LT recipients with successful VCTE examination between 2015 and 2022 were included. Presence of advanced fibrosis was defined as liver stiffness measurement (LSM) ≥10.5 kPa and hepatic steatosis as controlled attenuation parameter (CAP) ≥270 dB/m. The outcomes of interest included all-cause mortality, myocardial infarction (MI), and graft cirrhosis using cumulative incidence analysis that accounted for the competing risks of these outcomes. Results: The LSM was elevated in 64 (18%) and CAP in 163 (45%) LT recipients. The baseline LSM values were similar in patients with elevated vs normal CAP values. After a median follow-up of 65 (interquartile range, 20–140) months from LT to baseline VCTE, 66 (18%) patients died, 12 (3%) developed graft cirrhosis, and 18 (5%) experienced an MI. Baseline high LSM was independently associated with all-cause mortality (hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.11–3.50; P = .02) and new onset cirrhosis (HR, 6.74; 95% CI, 2.08–21.79; P < .01). A higher CAP value was significantly and independently associated with increased risk of experiencing a MI over study follow-up (HR, 4.14; 95% CI, 1.29–13.27; P = .017). Conclusions: The VCTE-based parameters are associated with clinical outcomes and offer the potential to be incorporated into clinical risk-stratification strategies to improve outcomes among LT recipients.
KW - Controlled Attenuation Parameter
KW - Liver Stiffness Measurement
KW - Liver Transplant
KW - Myocardial Infraction
KW - Vibration Controlled Transient Elastography
UR - http://www.scopus.com/inward/record.url?scp=85200340031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85200340031&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2024.06.020
DO - 10.1016/j.cgh.2024.06.020
M3 - Article
C2 - 38969073
AN - SCOPUS:85200340031
SN - 1542-3565
VL - 22
SP - 2424-2431.e4
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -